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Background: This study examines the extent to which relatives of severely ill cancer patients are involved in the
decision to limit treatment (DLT), their role in communicating patient wishes and the incidence of and reasons for
disagreement with relatives.
Patients and methods: This cohort study followed 70 patients with terminal cancer, for whom a limitation of life-
prolonging treatment was being considered. ‘Embedded researchers’ recorded patients’ wishes and the relatives’
roles and disagreements with DLT.
Results: Although 63 out of 70 patients had relatives present during their care, only 32% of relatives were involved in
DLT. Physicians were more likely to know the end-of-life (EOL) preferences for those patients who had visiting relatives
than those without them (78% versus 29%, P = 0.014). Most relatives supported patients in voicing their preferences
(68%), but one-third acted against the known or presumed wishes of patients (32%). Disagreements with patients’
relatives occurred in 21% of cases, and predominantly when relatives held views that contradicted known patient
preferences (71% versus 7%, P = 0.001).
Conclusion: If relatives are to play an important part in EOL decision making, we must devise strategies to recognise
their potential as patients’ advocates as well as their own needs.
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introduction
In the last few years, the role of families in end-of-life (EOL)
care has gained increasing attention, driven by the necessity of
surrogate decision making, especially in intensive care [1–3]
where up to 90% of deaths are preceded by a decision to limit
treatments (DLTs) [4]. Because <5% of patients are able to
communicate with clinicians at that time, families often serve as
informants regarding patient wishes [5]. There is a growing
consensus regarding the importance of shared decision making
in the intensive care unit (ICU), where clinicians and family
members collaborate on decisions about life-sustaining
treatments [6–8].
However, the role of relatives is less clear when the patient is
still able to communicate but is very sick or on the verge of
losing his or her decision-making capacity or when there is
reason to believe that the relatives’ preferences differ from the
patient’s wishes. Should relatives be viewed only as informants
about patient wishes or as advocates for patients’ preferences?
Or, should relatives have a say in treatment decisions as
‘natural’ surrogates, even though they lack a legal mandate? In
the case of disagreement, how can relatives’ own needs be
reconciled with the patient’s preferences? So far, there are little
empirical data about family involvement in DLT for non-ICU
patients. Existing studies almost exclusively originate from
ICUs and indeed they raise some concerns about family
involvement. Involved relatives showed a higher rate of
posttraumatic stress symptoms [9], many relatives experienced
disagreement with the health care team [10] and clinicians have
questioned whether relatives express authentic patient wishes.
To our knowledge, however, there are no data that document
the actual role of family members or the incidence and reasons
for disagreement about DLT in patients who are not
incapacitated at the time of decision making.
In this study, we took an on-site approach by utilising
‘embedded researchers’ on the wards [11], combining
observation of family involvement on daily rounds with
interviews with clinicians, patients and family members.
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We present results describing (i) the role of family members
in DLT, (ii) factors affecting family involvement and (iii) the
frequency and reasons for disagreement between clinicians,
patients and family in DLT.
methods
A prospective cohort study design was chosen including patients who were
admitted within a 15-month period to the Department of Haematology and
Oncology at the University of Munich Medical Centre. Patients older than
18 years were eligible if the question of forgoing or terminating treatment
options was being discussed. The decision-making process regarding
limiting treatment (DLT) was observed until the death of the patient or the
discharge to home or hospice. Either the patient or the legal substitute
decision-maker gave informed consent to participation in the study, which
was approved by the independent ethics committee of the institution.
data collection
In order to document the process of DLT as realistically as possible, a
structured documentation form (7 categories, 54 questions) was completed
by two embedded researchers trained to gather information in a standardised
manner [12]. It was based on chart review, structured enquiry of physicians
and patients and systematic follow-up on the decision-making process on a
daily basis until death or discharge of the patient. We reported patient
recruitment, data prioritisation and integration for patient involvement in
DLT before [12]. With regard to the role of relatives in DLT, the following
information was recorded:
(1) The availability of relatives defined as patients with visiting relatives.
(2) The role and involvement of family member in DLT as indicated by
physicians, patients or relatives and verified by the embedded
researchers’ observation.
(3) The incidence and reasons for disagreement with relatives.
(4) Family members’ influence of decision outcomes, especially in cases of
disagreement.
We defined a minimal standard for family involvement in the discussion
about DLT, which required that family members participate in the
discussion about EOL- care with the physician and that they be notified
when the physicians actually decided to limit treatment. To further
determine the relatives’ role in EOL- care, we observed what stance they
took on the patient’s EOL- care and whether their agenda differed from the
patient’s known or assumed preferences. This information was
supplemented by the embedded researchers’ documentation of the family’s
interaction with the patient during the interview and follow-up visits.
Finally, the relatives’ roles in communicating patient preferences were
stratified into three groups by an independent researcher: group 1), patients
whose relatives helped to make their preferences heard; group 2, patients
whose relatives’ agenda differed from known patient preferences; group 3,
patients who were unable to communicate, and whose providers questioned
whether family members’ wishes represented the authentic patient wishes.
Group 1 was summarised as family members supporting patient
preferences; groups 2 and 3 were combined in the category ‘family members
not supporting patient wishes’. These data were aligned with the following
information about the decision-making process from the patient and
physician perspective: Patient ability to communicate, patient wishes for
EOL- care and patient involvement in DLT
(5) Physicians’ knowledge of the patient’s EOL preferences and perceived
disagreement in DLT. The influence of relatives on decision outcomes
was analysed in cases where the family members’ views about the right
course of action differed from either the patient’s or clinician’s view
(disagreement cases). If their view prevailed in the final decision, we
concluded that family members had a strong influence on decision
outcomes.
Content validity was evaluated by consensus of an expert panel and reviews
of the literature. The documentation form was pretested in haematology–
oncology and had been used in a parallel collaborative study on DLT in
neonatology [13]; the form was further developed in a smaller in-depth case
series on DLT in intensive care [14]. All items of the documentation form
were encoded using the same coding conventions by two researchers.
statistical methods
Descriptive statistical analysis was carried out on patient characteristics,
their preferences for EOL- care, information about family members and
details about the decision process. To test whether differences in family
involvement or the role of relatives were associated with patient
characteristics, the Mann–Whitney test was used for numerical data and v2
test or Fisher’s exact test in cross tabulations. Two-tailed P values <0.05
were considered statistically significant. Multiple logistic regression analysis
was done to assess the strength and independence of effects of patient
characteristics, disagreements and role on involvement of relatives in DLT.
Data analysis was carried out using SPSS/Win, version 14.0 (SPSS Inc,
Chicago, IL).
See supplementary material (available in Annals of Oncology online) for
more details on the method of patient recruitment, data acquisition and
work up.
results
characteristics of patients with and without visiting
relatives
A majority of patients (63 out of 70) had relatives who were
present in patient care. Table 1 compares characteristics of
patients with and without available relatives. The two groups
showed a gender difference with all patients without relatives
being male (P = 0.016). While the presence of family members
had no significant influence on patient involvement in DLT,
physicians knew significantly more often about patient
preferences in patients with visiting relatives (78% versus 29%,
P = 0.014) (Table 1).
role of family members communicating the
patient’s wishes
The number of relatives sharing in patient care varied between
one and seven (median 1), with the spouse (59%) or children
(21%) being the primary contact person in most patients
(Table 2). Thirty patients were supported by their family
members in making their preferences heard (68%); in eight
patients (18%), relatives acted against the known wishes of the
patient, and in six patients (14%) who were unable to
communicate, clinicians thought relatives did not represent
authentic patient wishes. Five patients did not allow their
relatives to play an active role in decision making. They were
excluded from this analysis.
involvement of family members in DLT
Data about family involvement were available in 60 out of 63
patients with visiting relatives (Table 3). Relatives were
‘involved’ in the discussion about limiting treatment in only 19
(32%) and ‘informed’ about DLT in 35 patients (58%). Family
members of six patients were not included in the conversation
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about DLT: in three patients, this was because the patients
themselves had been not informed about DLT, in one case, the
patient did not want the relatives to be involved, and in two
cases, no information was available on why the family did not
participate. One would expect that a patient’s inability to
communicate would serve as a good predictor for family
involvement because relatives could serve as advocates for
incapacitated patients (Table 3, first column). Surprisingly,
relatives of patients with limited ability to communicate were
not involved more often in DLT than relatives of patients who
could speak for themselves. Relatives’ involvement in DLT did
also not change significantly over the time of the disease.
Actually, the main predictor for the involvement of relatives
was the involvement of the patient himself or herself: 15
involved patients had their relatives involved in DLT (47%) as
compared with only 4 patients (14%) who had not been
involved in DLT themselves (P = 0.001). Whether patients
opted for quality or length of life was associated with their
coping strategy: 23 of 26 patients with realistic coping strategies
preferred treatment focusing on quality of life, whereas only 3 of
12 patients in denial did so (88% versus 25%, P = 0.005). As a
consequence, relatives of patients in denial were involved less
often than relatives of patients with an appropriate perception of
their situation (7% versus 50%, P = 0.013) (Table 2, first
column). The data about the coping behaviour of patients with
active family members were covered by four sources of
information in 4 patients, by three sources in 9 patients, by two
sources in 13 patients and one source in 15 patients.
Binary logistic regression analysis of the association between
involvement of family members and patient age, Karnofsky
performance index, ability to communicate and disagreement
with relatives showed no significant influence on any parameter
(data not shown).
incidence and reasons for disagreement with
relatives and relatives impact on decision
outcomes
Disagreement in the interaction with relatives was observed in
13 out of 63 patients (21%). It occurred more often in patients
whose relatives did not support patient wishes as compared
with patients whose relatives did (71% versus 7%, P = 0.001)
(Table 3, second column). We observed a weak tendency of
more disagreements occurring with relatives as the disease
duration of the disease extends (P = 0.645): disagreements
occurred in 15% of patients with <1 year of disease duration, in
18% of patients with 1–2 years of disease duration and in 27%
of patients being diagnosed >3years ago (P = 0.64).
Disagreement occurred within the families of seven patients
(54%), between the physician and the family/patient in four
patients and between the family and the physician/patient in
two cases (Table 4). The most frequent source of disagreements
regarded treatment goals (eight patients/61%). Four patients
wished to be discharged to home, but family preferred them to
stay hospitalised. Family members did influence treatment
outcomes in 7 out of 13 disagreement cases (54%). Their
influence on the final decision was strongest regarding
discharge and hospitalisation; all four disagreements were
resolved the way the relatives preferred. In disagreements about
DLT, the relatives’ views prevailed in the final decision in two
out of eight cases (Table 4).
Table 1. Comparative characteristics of patients with and without involved relatives; significant differences between the groups are highlighted by bold
P-values
No. of patients in subgroups All patients
(n = 70)
Patients with
relatives (n = 63)
Patients without
relatives (n = 7)
P
Age, median (range) 60 (30–82) 60 (30–82) 56 (50–69) 0.88
Karnofsky performance scale, median (range) 50 (10–90) 50 (10–90) 50 (30–90) 0.44
Sex, No. (%) 0.016
Female 30 (43) 30 (48) 0 (0)
Male 40 (57) 33 (52) 7 (100)
Patient preferences known to medical team, No. (%) 0.014
Yes 51 (73) 49 (78) 2 (29)
Patient prefers quality of life 36 35 (71) 1
Patient prefers length of life 15 14 (29) 1
No 19 (27) 14 (22) 5 (71)
Patient involvement, No. (%) 0.24
Involved in DLT 34 (49) 32 (51) 2 (29)
Not involved 36 (51) 31 (49) 5 (71)
Patient coping, No. (%) 0.19
Realistic 27 (39) 26 (41) 1 (14)
Denial 16 (22) 14 (22) 2 (29)
Missing data 27 (39) 23 (37) 4 (57)
Ability to communicate, No. (%) 0.75
Possible 38 (54) 34 (54) 4 (57)
Reduced due to primary cognitive limitations 21 (30) 19 (30) 2 (28)
Reduced due to cognitive deterioration 7 (10) 7 (11) 0 (0)
Reduced due to language barrier 4 (6) 3 (4) 1 (14)
Annals of Oncology original article
Volume 22 | No. 12 | December 2011 doi:10.1093/annonc/mdr019 | 2669
discussion
In this prospective cohort study, we described the roles that
relatives play in DLT in patients with end-stage malignant
disorders. The key findings about the caregivers’ roles in EOL
decision making were that (i) two-thirds of relatives acted as
advocates for their patient’s preferences, but only one-third
were actually involved in DLT. (ii) Also, relatives of patients
who were unable to communicate were involved less often as
‘natural’ surrogates than a shared decision-making approach to
DLT would suggest. (iii) Disagreement with family members
occurred with one out of every five patients, chiefly when
relatives held views that differed from known patient
preferences. Such views differed in about one-third of patients
and this is probably a major source of distress for family,
patients and providers [15].
the roles of patient relatives: advocates or ‘natural’
surrogates in DLT?
Relatives were actively involved in DLT in one-third of the cases.
This falls well within the proportion of family involvement that
has been reported for the intensive care setting, a measure that
varies from 17% to 44% in European countries [16, 17].
Contrary to our expectation that relatives would function as
‘natural’ surrogates, family members of patients who could not
speak for themselves were not involved more frequently. This is
striking in the light of studies suggesting that most patients want
their families to act as representatives if they become
incapacitated. Our data show that actually two-thirds of
relatives did support their patients in voicing their preferences
and acted as their advocates in DLT [18, 19].
Three reasons may explain the low frequency of family
members’ involvement. First, in the majority of cases, there was
no need for relatives to advocate patient preferences since all
participants agreed on comfort care. Second, non-involvement
of family members may have resulted from the physicians’ strict
interpretation of the legal requirements for patients without
formal surrogate designation. Unauthorised family members of
incompetent adult patients may, according to German and
most (Central) European legislations, only serve as informants
of the presumed wishes of their patient [2, 3]. Third, relatives
of patients in denial were significantly less often involved in
DLT than those of patients with realistic coping behaviour. It
has been shown before that most of the patients in denial did
not agree with the palliative care recommendations of their
physicians and had not been involved in the actual DLT [12].
are family members authentic advocates for
patient preferences?
Two-thirds of patients were supported by their relatives in
making their wishes heard; in one-third, relatives held different
views about the right course of action. The incidence of
disagreement between family members and clinicians was high
when relatives held (i) a view that differed from the known
patient wishes or (ii) a view that was challenged by clinicians as
not representing the patient’s authentic wishes.
While for the former group (i) it is documented that relatives
followed their own preferences, we do not have information on
the latter group (ii) to substantiate the physicians’ doubts.
Clinicians’ doubts that family members acted as appropriate
patient representatives have been reported across a broad range
of cultures in North America and Europe [20]. In a study in
French ICUs, half of those intensive care specialists who were
unwilling to involve family members gave as their main reason a
tendency of families to express their own wishes rather
than those of the patient [21]. In our study, this concern is
warranted in one-third of patients, whereas family members did
act as authentic advocates for the patient in two-thirds of cases.
There are controversial data on how accurate family members
and physicians are at predicting patient preferences, suggesting
that neither are more accurate than a coin toss [22–24].
incidence and reasons for disagreement with
relatives and their influence on decision outcomes
Disagreement with family members during DLT was observed
in 21% of patients. The number of disagreements reported in
the literature varies widely from 10% [25] to as high as 78%
[26] of patients in whom EOL decisions had to be made. This
variation may in part be explained by the likelihood of
perceived disagreements increasing with the number of persons
Table 2. Characteristics of family members [No. (%)] and frequency of
decisions to limit life-prolonging treatment
No. (%)
Patients with relatives
Present 63 (90)
Not present 4 (6)
Nonexistent 3 (4)
Number of relatives sharing in patient care
No relatives 7 (10)
One relative 35 (50)
Two relatives 16 (23)
Three relatives 8 (11)
More than three relatives 4 (6)
Primary contact persons within the family
Spouse 37 (59)
Children 13 (21)
Siblings 1 (2)
Others 3 (5)
No data 9 (14)
Role of relatives in communicating the
patient’s wishes for EOL care
n = 44
Actively supporting 30 (68)
Acting against patient wishes 8 (18)
Impeached surrogacy 6 (14)
Decisions to limit life-prolonging treatment included
No resuscitation 56 (80)
No transfer to ICU 42 (60)
No chemotherapy 13 (18)
No radiation 2 (3)
No surgery 3 (4)
No antibiotics 3 (4)
No bone marrow transplantation 2 (3)
EOL, end-of-life care; ICU, intensive care unit.
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interviewed. In one of the few studies that focused on
disagreement in EOL decision making, the incidence of
disagreement between family and staff (33%) was similar to our
proportion of 31% of disagreement between physician and
family in alliance with the patient [26].
Disagreements about DLT have gained much attention in the
literature and were the most common cause of conflict in this
study [15], with six out of eight disagreements arising because
relatives preferred a more aggressive treatment than the patient
and the physicians. This resonates with studies that report
relatives find DLT more difficult than does the patient [27]. We
also found that discharge to home or to hospice caused
disagreement in a significant number of cases; these issues
might be specific to severely ill patients in the non-ICU setting.
While physicians were responsive to the relatives’ preferences
concerning discharge to home or hospice in all disagreement
cases, they gave precedence to the patients’ preferences in most
disagreements about DLT (Table 4).
This study has several limitations. While we did not ask
relatives directly about their preferred role in decision making,
we know from previous studies that most relatives prefer an
active role in decision- making, but only 15%–30% who prefer
to leave decisions with the physician [6, 21]. It seems very likely
that relatives would have wished to participate in DLT in more
than the observed one-third of patients.
We did not ask the physicians how they conceptualise the
role of relatives in DLT and why they did not involve some
family members. Physicians may have wanted to protect family
members from burdensome involvement [9]. Furthermore,
studies show that shared decision making in EOL decisions is
often incomplete with the family’s role being the least
frequently discussed element [7, 12].
Table 3. Comparison of characteristics of patients whose relatives were involved in decisions to limit treatment and whose relatives were not involved
(pale grey sheaded columns), and of patients whose relatives supported their preferences for end-of-life care and those whose relatives pursuit goals that
differed from patient goals (darker grey shaded columns); significant differences between the groups are highlighted by bold P-values
No. of patients in subgroups Relatives
involved
(n = 19)
Relatives
not involved
(n = 41)
P Relatives supporting
patient wishes
(n = 30)a
Relatives not
supporting patient
wishes (n = 14)a
P
Age, median (range) 60 (30–82) 60 (33–77) 0.85 59.5 (30–82) 61 (32–76) 0.62
Karnofsky performance
scale, median (range)
40 (10–90) 50 (10–90) 0.34 45 (10–90) 50 (20–90) 0.65
Communication, No. (%) 0.51 0.81
Possible 11 (35) 20 (65) 14 (70) 6 (30)
Limited/not possible 8 (28) 21 (72) 16 (67) 8 (33)
Disease durationb, No. (%) 0.24 0.84
<1 year (versus 1–3 years) 6 (23) 20 (77) 0.20 13 (68) 6 (32) 0.59
1–3 years (versus 3 years) 7 (41) 10 (59) 0.12 10 (77) 3 (23) 0.59
>3 years (versus <1 year) 2 (15) 11 (85) 0.58 6 (67) 3 (33) 0.93
Patient involvement, No. (%) 0.001 0.98
Involved in DLT 15 (47) 17 (53) 17 (56) 8 (57)
Not involved 4 (14) 24 (86) 13 (44) 6 (43)
Disagreement with relatives,
No. (%)
0.55 0.001
No 14 (74) 33 (80) 28 (93) 4 (29)
Yes 5 (26) 8 (20) 2 (7) 10 (71)
Patient preference for
EOL care, No. (%)
0.39 0.102
Quality of life 13 (76) 20 (65) 20 (83) 7 (58)
Length of life 4 (24) 11 (35) 4 (17) 5 (42)
Missing data 2 10 6 2
Patient coping, No. (%) 0.013 0.53
Realistic 13 (93) 13 (50) 14 (77) 6 (66)
Denial 1 (7) 13 (50) 4 (23) 3 (34)
Missing data 5 15 12 5
Physician patient disagreement
about DLT, No. (%)
0.32 0.05
No 14 (87) 23 (77) 21 (95) 9 (69)
Yes 2 (13) 7 (23) 1 (5) 4 (31)
No data on patient preferences 3 11 8 1
aSecond column includes only patients whose relative’s role was known: relatives either supported the patient’s wishes or acted against them (n = 44).
bAll three groups were tested against each other.
EOL-care, end-of-life care.
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Table 4. Overview of all conflict cases with description of patient preferences, physician’s treatment goals and preferences of family members as well as their influence on decision outcomes
No. Patient
preference
Physician’s
recommendation
Disagreeing
parties
Description of
disagreement
Patient’s ability
to communicate
Relatives supporting
patient wishes
Final decision Influence on
final decision
Disagreement about
treatment goals
1 Comfort care Comfort care Patient/physician-
relative
Patients’ husband asks
for active treatment
Given No Comfort care No
2 Comfort care Comfort care Patient/physician-
relative
Patients’ son insists
on active treatment
Given No Comfort care No
3 Comfort care Comfort care Disagreement
between
relatives
Patients’ daughter
supports patient wish,
but all other relatives want the
patient to transfer to another
hospital for active treatment
Limited Contested
surrogacy
Comfort care No
4 Comfort care Comfort care Patient-relatives Spouse insists on active treatment.
Patient does not protest
Limited No Active treatment Yes
5 Active treatment Comfort care Patient/relatives-
physician
Relatives prefer active treatment
in the beginning, but after
conversation with the
physicians they preferred
comfort care
Given No Comfort care Probably no
6 Active treatment
then comfort care
Comfort care Physician-relatives Patient changes his mind as his
condition deteriorates. Patients’
son insists on active treatment
Limited No Comfort care No
7 Active treatment Comfort care Patient-relative Husband does not want to extend
the suffering of his wife,
votes for comfort care
Limited Contested
surrogacy
Comfort care Probably no
8 Comfort care then
active treatment
Comfort care Physician-relatives Patient was persuaded by family
members to take the risk of an
operation with questionable
benefit
Limited No Operation
(no DLT)
Yes
Disagreement about discharge to home or disclosure
9 Discharge to
daughter’s home
Discharge to home Disagreement
between
relatives
Daughter supports patient wish.
Husband wants the patient to
stay in the hospital or be
transferred to Turkey to other
relatives
Limited Yes Discharge to
daughters home
Yes
10 No preference
known
Discharge to hospice Physician-relative Patient’s wife wants the patient
to stay in the hospital because
the patient is so weak.
Patient stayed and died
a few days later
Limited Yes No discharge Yes
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conclusions
Our data suggest that the clinical practice for non-ICU cancer
patients does not encourage family members routinely to
participate in DLT. Physicians should utilise the full potential
of relatives as advocates for patient preferences, especially in
incapacitated patients who may benefit from the voices of
relatives. However, if relatives are allowed to weigh in on EOL
decisions, physicians need to ascertain that these relatives
express authentic patient wishes. Therefore, physicians first
need to learn whether patients want their relatives to
participate in DLT and about the patients’ preferences and
their relatives’ needs. Our study shows that patients in denial,
as well as their relatives require particular attention and
support from clinicians to enhance appropriate coping and to
share decision making. Just as we needed studies and training
to learn how to involve patients appropriately in EOL
decisions [28], we now need strategies to ensure family
participation that is in the best interest of both patients and
relatives.
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